中性粒细胞明胶酶相关脂质运载蛋白在冠心病中的研究进展

doi:10.12114/j.issn.1007-9572.2020.00.096

摘要/Abstract

摘要： 近年来心脏标志物领域有了飞速的发展，推动了整体心血管疾病诊断水平的提高。研究表明，中性粒细胞明胶酶相关脂质运载蛋白（NGAL）作为急性肾损伤（AKI）的一种标志物，与冠心病患者疾病的严重程度、不良预后及未来心血管事件的发生相关，是冠心病领域的潜力标志物。本文就NGAL的来源与性质及NGAL与冠状动脉病变严重程度、稳定型冠心病、急性冠脉综合征（ACS）、未来冠心病事件的关系的研究进展做一综述，希望能够为冠心病生物标志物领域的研究提供新的参考方向。

关键词: 冠心病, 中性粒细胞明胶酶相关脂质运载蛋白, 生物标志物, 冠状动脉病变, 稳定型冠心病, 急性冠脉综合征, 未来冠心病事件

Abstract: In recent years，the rapid development of cardiac markers has improved the overall level of cardiovascular disease's diagnosis.Research findings have shown that neutrophil gelatinase-associated lipocalin（NGAL），as a marker of acute renal injury（AKI），is closely related to the severity of coronary heart disease，adverse prognosis and the occurrence of future cardiovascular events.NGAL is also a potential marker in coronary heart disease.The purpose of this review is to elucidate the origin and nature of NGAL and the relationship between NGAL and the severity of coronary artery disease，stable coronary heart disease，acute coronary syndrome（ACS）and future coronary heart disease events.And it aims to provide a promising reference direction for the researches of biomarkers in coronary heart disease.

Key words: Coronary disease, Neutrophil gelatinase-associated lipocalin, Biomarkers, Coronary artery disease, Stable coronary heart disease, Acute coronary syndrome, Future coronary heart disease events

崔小豪,杨志明. 中性粒细胞明胶酶相关脂质运载蛋白在冠心病中的研究进展[J]. 中国全科医学, 2020, 23(27): 3492-3495. DOI: 10.12114/j.issn.1007-9572.2020.00.096.
CUI Xiaohao,YANG Zhiming. Research Progress of Neutrophil Gelatinase-associated Lipocalin in Coronary Heart Disease　[J]. Chinese General Practice, 2020, 23(27): 3492-3495. DOI: 10.12114/j.issn.1007-9572.2020.00.096.

参考文献

［1］PIEPOLI M F，CORRà U，DENDALE P，et al．Challenges in secondary prevention after acute myocardial infarction：a call for action［J］．Eur J Cardiovasc Nurs，2017，16（5）：369-380．DOI：10.1177/1474515117702594.
［2］KHAWAJA S，JAFRI L，SIDDIQUI I，et al．The utility of neutrophil gelatinase-associated Lipocalin（NGAL）as a marker of acute kidney injury（AKI）in critically ill patients［J］．Biomark Res，2019，7：4．DOI：10.1186/s40364-019-0155-1.
［3］KJELDSEN L，JOHNSEN A H，SENGEL?V H，et al．Isolation and primary structure of NGAL，a novel protein associated with human neutrophil gelatinase［J］．J Biol Chem，1993，268（14）：10425-10432.
［4］PEDERSEN K R，RAVN H B，HJORTDAL V E，et al．Neutrophil gelatinase-associated lipocalin（NGAL）：validation of commercially available ELISA［J］．Scand J Clin Lab Invest，2010，70（5）：374-382．DOI：10.3109/00365513.2010.486868.
［5］HELANOVA K，SPINAR J，PARENICA J.Diagnostic and prognostic utility of neutrophil gelatinase-associated lipocalin（NGAL）in patients with cardiovascular diseases——review［J］．Kidney Blood Press Res，2014，39（6）：623-629．DOI：10.1159/000368474.
［6］PRECEK J，HUTYRA M，KOVáCIK F，et al．Biomarkers of renal function in prognostic stratification of patients with acute coronary syndrome［J］．Cor Vasa，2018，60（2）：e148-154．DOI：10.1016/j.crvasa.2017.05.018.
［7］HEMDAHL A L，GABRIELSEN A，ZHU C Y，et al．Expression of neutrophil gelatinase-associated lipocalin in atherosclerosis and myocardial infarction［J］．Arterioscler Thromb Vasc Biol，2006，26（1）：136-142．DOI：10.1161/01.ATV.0000193567.88685.f4.
［8］EILENBERG W，STOJKOVIC S，PIECHOTA-POLANCZYK A，et al．Neutrophil gelatinase-associated lipocalin（NGAL）is associated with symptomatic carotid atherosclerosis and drives pro-inflammatory state in vitro［J］．Eur J Vasc Endovasc Surg，2016，51（5）：623-631．DOI：10.1016/j.ejvs.2016.01.009.
［9］SUNG H K，CHAN Y K，HAN M，et al．Lipocalin-2（NGAL）attenuates autophagy to exacerbate cardiac apoptosis induced by myocardial ischemia［J］．J Cell Physiol，2017，232（8）：2125-2134．DOI：10.1002/jcp.25672.
［10］ZOGRAFOS T，HALIASSOS A，KOROVESIS S，et al．Association of neutrophil gelatinase-associated lipocalin with the severity of coronary artery disease［J］．Am J Cardiol，2009，104（7）：917-920．DOI：10.1016/j.amjcard.2009.05.023.
［11］SOYLU K，AKSAN G，NAR G，et al．Serum neutrophil gelatinase-associated lipocalin levels are correlated with the complexity and the severity of atherosclerosis in acute coronary syndrome［J］．Anatol J Cardiol，2015，15（6）：450-455．DOI：10.5152/akd.2014.5513.
［12］KATAGIRI M，TAKAHASHI M，DOI K，et al．Serum neutrophil gelatinase-associated lipocalin concentration reflects severity of coronary artery disease in patients without heart failure and chronic kidney disease［J］．Heart Vessels，2016，31（10）：1595-1602．DOI：10.1007/s00380-015-0776-8.
［13］李超，彭瑜，高涵翔，等．血浆中性粒细胞明胶酶相关脂质运载蛋白水平与急性ST段抬高型心肌梗死病变严重程度的关系［J］．中国循环杂志，2018，33（3）：222-226．DOI：10.3969/j.issn.1000-3614.2018.03.004.
LI C，PENG Y，GAO H X，et al．Relationship between plasma level of neutrophil gelatinase-associated lipocalin and coronary lesion severity in patients with acute ST-elevation myocardial infarction［J］．Chinese Circulation Journal，2018，33（3）：222-226．DOI：10.3969/j.issn.1000-3614.2018.03.004.
［14］MALYSZKO J，BACHORZEWSKA-GAJEWSKA H，MALYSZKO J S，et al．Serum neutrophil gelatinase-associated lipocalin as a marker of renal function in hypertensive and normotensive patients with coronary artery disease［J］．Nephrology（Carlton），2008，13（2）：153-156．DOI：10.1111/j.1440-1797.2007.00899.x.
［15］PAULSSON J，DADFAR E，HELD C，et al．Activation of peripheral and in vivo transmigrated neutrophils in patients with stable coronary artery disease［J］．Atherosclerosis，2007，192（2）：328-334．DOI：10.1016/j.atherosclerosis.2006.08.003.
［16］CHAKRABARTI S，PATEL K D.Regulation of matrix metalloproteinase-9 release from IL-8-stimulated human neutrophils［J］．J Leukoc Biol，2005，78（1）：279-288．DOI：10.1189/jlb.1004612.
［17］SIVALINGAM Z，ERIK MAGNUSSON N，GROVE E L，et al．Neutrophil gelatinase-associated lipocalin（NGAL）and cardiovascular events in patients with stable coronary artery disease［J］．Scand J Clin Lab Invest，2018，78（6）：470-476．DOI：10.1080/00365513.2018.1499956.
［18］LINDBERG S，PEDERSEN S H，MOGELVANG R，et al．Prognostic utility of neutrophil gelatinase-associated lipocalin in predicting mortality and cardiovascular events in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention［J］．J Am Coll Cardiol，2012，60（4）：339-345．DOI：10.1016/j.jacc.2012.04.017.
［19］ZYKOV M V，KASHTALAP V V，BYKOVA I S，et al．Clinical and prognostic value of serum neutrophil gelatinase-associated lipocalin in patients with ST-segment elevation myocardial infarction［J］．Kardiologiia，2016，56（5）：24-29．DOI：10.18565/cardio.2016.5.24-29.
［20］LIM Y M，MOON J Y，MIN D，et al．Serial measurements of neutrophil gelatinase-associated lipocalin：prognostic value in patients with ST-segment elevation myocardial infarction treated with a primary percutaneous coronary intervention［J］．Coron Artery Dis，2017，28（8）：690-696．DOI：10.1097/MCA.0000000000000542.
［21］FAN Y，ZOU C.Prognostic value of neutrophil gelatinase-associated lipocalin in patients with acute ST-segment elevation myocardial infarction：a meta-analysis［J］．Eur J Prev Cardiol，2019，26（4）：444-446．DOI：10.1177/2047487318783254.
［22］NYMO S H，HARTFORD M，UELAND T，et al．Serum neutrophil gelatinase-associated lipocalin（NGAL）concentration is independently associated with mortality in patients with acute coronary syndrome［J］．Int J Cardiol，2018，262：79-84．DOI：10.1016/j.ijcard.2018.03.028.
［23］LAHIRI A，ALEX A G，GEORGE P V.Estimating the prevalence of elevated plasma neutrophil gelatinase associated lipocalin level in patients with acute coronary syndromes and its association with outcomes［J］．Indian Heart J，2018，70（2）：220-224．DOI：10.1016/j.ihj.2017.06.005.
［24］SHALENKOVA M A，MIKHAILOVA Z D，KLIMKIN P F.NGAL as a marker for some extrarenal complications in acute coronary syndrome［J］．Kardiologiia，2018（S3）：19-26.
［25］MARTíNEZ-MARTíNEZ E，BUONAFINE M，BOUKHALFA I，et al．Aldosterone target NGAL（neutrophil gelatinase-associated lipocalin）is involved in cardiac remodeling after myocardial infarction through NFκB pathway［J］．Hypertension，2017，70（6）：1148-1156．DOI：10.1161/HYPERTENSIONAHA.117.09791.
［26］NAKA K K，PAPATHANASSIOU K，BECHLIOULIS A，et al．Association of vascular indices with novel circulating biomarkers as prognostic factors for cardiovascular complications in patients with type 2 diabetes mellitus［J］．Clin Biochem，2018，53：31-37．DOI：10.1016/j.clinbiochem.2017.12.010.
［27］CHONG J J H，PRINCE R L，THOMPSON P L，et al．Association between plasma neutrophil gelatinase-associated lipocalin and cardiac disease hospitalizations and deaths in older women［J］．J Am Heart Assoc，2019，8（1）：e011028．DOI：10.1161/JAHA.118.011028.
［28］FASSETT R G，ROBERTSON I K，BALL M J，et al．Effects of atorvastatin on NGAL and cystatin C in chronic kidney disease：a post hoc analysis of the LORD trial［J］．Nephrol Dial Transplant，2012，27（1）：182-189．DOI：10.1093/ndt/gfr193.
［29］LáBR K，?PINAR J，PARENICA J，et al．Renal functions and prognosis stratification in chronic heart failure patients and the importance of neutrophil gelatinase-associated lipocalin［J］．Kidney Blood Press Res，2018，43（6）：1865-1877．DOI：10.1159/000495819.
［30］CHEN S，CHEN X C，LOU X H，et al．Determination of serum neutrophil gelatinase-associated lipocalin as a prognostic biomarker of acute spontaneous intracerebral hemorrhage［J］．Clin Chim Acta，2019，492：72-77．DOI：10.1016/j.cca.2019.02.009.
［31］MOSCHEN A R，ADOLPH T E，GERNER R R，et al．Lipocalin-2：a master mediator of intestinal and metabolic inflammation［J］．Trends Endocrinol Metab，2017，28（5）：388-397．DOI：10.1016/j.tem.2017.01.003.
［61］MATSUSHITA S，YONEKURA K，MERA K，et al．Successful treatment of metastatic extramammary Paget's disease with S-1 and docetaxel combination chemotherapy［J］．J Dermatol，2011，38（10）：996-998．DOI:10.1111/j.1346-8138.2010.01149.x.
［62］BELEZNAY K M，LEVESQUE M A，GILL S.Response to 5-fluorouracil in metastatic extramammary Paget disease of the scrotum presenting as pancytopenia and back pain［J］．Curr Oncol，2009，16（5）：81-83．DOI:10.3747/co.v16i5.374.
［63］TAKAHAGI S，NODA H，KAMEGASHIRA A，et al．Metastatic extramammary Paget's disease treated with paclitaxel and trastuzumab combination chemotherapy［J］．J Dermatol，2009，36（8）：457-461．DOI:10.1111/j.1346-8138.2009.00676.x.
［64］MOCHITOMI Y，SAKAMOTO R，GUSHI A，et al．Extramammary Paget's disease/carcinoma successfully treated with a combination chemotherapy：report of two cases［J］．J Dermatol，2005，32（8）：632-637．DOI:10.1111/j.1346-8138.2005.tb00812.x.
［65］WATANABE Y，HOSHIAI H，UEDA H，et al．Low-dose mitomycin C，etoposide，and cisplatin for invasive vulvar Paget's disease［J］．Int J Gynecol Cancer，2002，12（3）：304-307．DOI:10.1046/j.1525-1438.2002.01126.x.
［66］AL HALLAK M N，ZOUAIN N.Extramammary perianal Paget's disease［J］．Case Rep Gastroenterol，2009，3（3）：332-337．DOI:10.1159/000256382.
［67］ZOLLO J D，ZEITOUNI N C.The Roswell park cancer institute experience with extramammary Paget's disease［J］．Br J Dermatol，2000，142（1）：59-65．DOI:10.1046/j.1365-2133.2000.03242.x.
［68］YE J N，RHEW D C，YIP F，et al．Extramammary Paget's disease resistant to surgery and imiquimod monotherapy but responsive to imiquimod combination topical chemotherapy with 5-fluorouracil and retinoic acid：a case report［J］．Cutis，2006，77（4）：245-250.
［69］ITO T，KAKU Y，NAGAE K，et al．Tumor thickness as a prognostic factor in extramammary Paget's disease［J］．J Dermatol，2015，42（3）：269-275．DOI:10.1111/1346-8138.12764.
［70］KARAM A，DORIGO O.Treatment outcomes in a large cohort of patients with invasive extramammary Paget's disease［J］．Gynecol Oncol，2012，125（2）：346-351．DOI:10.1016/j.ygyno.2012.01.032.
［71］HERREL L A 1，WEISS A D，GOODMAN M，et al．Extramammary Paget's disease in males:survival outcomes in 495 patients［J］.Ann Surg Oncol，2015，22（5）:1625-1630．DOI：10.1245/s10434-014-4139-y.
［72］WANG Z，LU M，DONG G Q，et al．Penile and scrotal Paget's disease:130 Chinese patients with long-term follow-up［J］.BJU Int，2008，102（4）：485-488．DOI:10.1111/j.1464-410X.2008.07575.x.

[1]	周启保, 罗潇, 陈玲, 曹俊达, 李菊香, 徐劲松, 苏海. 收缩压昼夜变异率联合正常RR间期标准差对冠心病诊断价值的临床研究[J]. 中国全科医学, 2025, 28(30): 3760-3765.
[2]	吴文俊, 卫靖靖, 李雪, 任红杰, 于瑞, 彭广操, 朱明军. 基于隐结构模型结合关联规则分析冠心病合并高血压的方药规律[J]. 中国全科医学, 2025, 28(30): 3787-3795.
[3]	李玲, 李雅萍, 钱时兴, 聂婧, 陆春华, 李霞. 社区中老年人认知功能影响因素及风险预测研究[J]. 中国全科医学, 2025, 28(30): 3773-3778.
[4]	李嘉欣, 刘钟桧, 谢硕, 付志方, 孙丹, 焦红梅. 分解代谢及炎症状态的生物标志物变化趋势对老年患者慢性危重症的早期预测价值研究[J]. 中国全科医学, 2025, 28(24): 2993-2999.
[5]	杨继, 张垚, 赵英强, 张秋月. 中医三级防控模式对冠心病与脑卒中患者的管理效能评价：一项单中心前瞻性队列研究[J]. 中国全科医学, 2025, 28(22): 2750-2761.
[6]	贺婷, 李佳, 谭文彬. 循环系统疾病与继发性骨质疏松症的研究新进展[J]. 中国全科医学, 2025, 28(17): 2101-2112.
[7]	绳菁煜, 刘凡凡, 马梅, 田霖, 刘雨桐, 刘凤敏, 高杉, 于春泉. 冠心病患者血尿素氮与血清白蛋白比值与颈动脉斑块的相关性研究[J]. 中国全科医学, 2025, 28(15): 1831-1839.
[8]	宋洪娜, 许洪梅, 刘玉环, 王青龙, 汤云昭, 于翔. 冠心病合并糖尿病患者经皮冠状动脉介入治疗术后共病随访模式的构建及应用效果研究[J]. 中国全科医学, 2025, 28(14): 1737-1743.
[9]	柴依依, 叶青芳, 林平, 李玲. 寒地城市冠心病患者运动认知风险综合征发生现状及影响因素研究[J]. 中国全科医学, 2025, 28(14): 1730-1736.
[10]	黄传应, 廖晓阳, 杨荣, 李东泽, 张鹏, 贾禹, 刘力滴. 2024年《女性心脏急症管理》临床声明解读[J]. 中国全科医学, 2025, 28(12): 1427-1432.
[11]	贾硕, 程功, 关蕾, 冯盼盼, 许百灵, 方伟, 张骥. 单电子发射计算机断层成像技术在经皮冠状动脉支架植入术后患者冠脉微循环障碍中的诊断性能研究[J]. 中国全科医学, 2025, 28(09): 1122-1127.
[12]	马晓萱, 王荣琦. 代谢组学在肝细胞癌诊疗中的研究进展[J]. 中国全科医学, 2025, 28(08): 1017-1022.
[13]	岳海涛, 何婵婵, 成羽攸, 张森诚, 吴悠, 马晶. 基于机器学习的冠心病风险预测模型构建与比较[J]. 中国全科医学, 2025, 28(04): 499-509.
[14]	杨红, 刘成, 刘森, 邵琪琪, 夭元昊, 付真彦. 残余胆固醇与进展为主要不良心血管事件的非罪犯病变易损斑块的相关性研究[J]. 中国全科医学, 2025, 28(03): 299-304.
[15]	张铭, 王文娟, 郝问, 陈吉彬, 夏伟, 邵一兵, 王宾. 阻塞性睡眠呼吸暂停与急性冠脉综合征的相关性：临床研究的现状及展望[J]. 中国全科医学, 2025, 28(03): 257-261.